• PDF / 168,873 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 104 Downloads / 158 Views

DOWNLOAD

REPORT

---

1 S

Grade 3 pancytopenia: case report In a case series of 18 male patients with high tumour burden (miTNM classification, PROMISE), low PSA-doubling time of less than 2 months and metastatic castration-resistant prostate cancer (mCRPC), a male patient [exact age not stated] was described, who developed grade 3 pancytopenia following treatment with PSMA-617 [Lu-177-PSMA-617 radio-ligand therapy]. Treatment with PSMA-617 was discontinued after 7 cycles due to pancytopenia [dosage, route, duration of treatment to reaction onset and outcome not stated]. Mader N, et al. Extended therapy with Lu-177-PSMA-617 in patients with high tumor load metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine 61 803514823 (Suppl. 1): May 2020 [abstract]

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830